Progress in reducing nausea and emesis. Comparisons of ondansetron (zofran), granisetron (kytril), and tropisetron (navoban)

Cancer

Volumn 76, Issue 3, 1995, Pages 343-357

  Morrow, Gary R ^a   Hickok, Jane T ^a   Rosenthal, Susan N ^a  

^a UNIVERSITY OF ROCHESTER   (United States)

Author keywords

chemotherapy; emesis; granisetron; nausea; ondansetron; serotonin antagonists; tropisetron; vomiting

Indexed keywords

ALIZAPRIDE; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; BENZODIAZEPINE DERIVATIVE; BUTYROPHENONE DERIVATIVE; CANNABINOID; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIAZEPAM; DIPHENHYDRAMINE; DRONABINOL; DROPERIDOL; EPIRUBICIN; FLUOROURACIL; GRANISETRON; HALOPERIDOL; IFOSFAMIDE; LORAZEPAM; METHYLPREDNISOLONE; METOCLOPRAMIDE; ONDANSETRON; PHENOTHIAZINE DERIVATIVE; PROCHLORPERAZINE; SEROTONIN ANTAGONIST; THIETHYLPERAZINE; TROPISETRON; UNINDEXED DRUG;

AMNESIA; ANXIETY; BEHAVIOR THERAPY; CANCER; CANCER CHEMOTHERAPY; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONSTIPATION; DRUG EFFICACY; DRUG INDUCED DISEASE; EXTRAPYRAMIDAL SYMPTOM; HEADACHE; HUMAN; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; NAUSEA; ORAL DRUG ADMINISTRATION; PARENTERAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RECTAL DRUG ADMINISTRATION; REVIEW; SEDATION; SUBLINGUAL DRUG ADMINISTRATION; VOMITING;

ANTIEMETICS; ANTINEOPLASTIC AGENTS; COMPARATIVE STUDY; GRANISETRON; HUMAN; INDOLES; NAUSEA; ONDANSETRON; SEROTONIN ANTAGONISTS; VOMITING;

EID: 0029073652     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/1097-0142(19950801)76:3<343::AID-CNCR2820760302>3.0.CO;2-V     Document Type: Review

References (121)

1. A biobehavioral model of patient‐reported nausea: implications for clinical practice
2. Mechanisms and management of chemotherapy‐induced nausea and vomiting
3. Review: the management of nausea and vomiting in clinical oncology
4. The assessment of nausea and vomiting: post problems, current issues, and suggestions for future research
5. Pharmacologic treatment of chemotherapy‐induced nausea and vomiting
6. Managing chemotherapy‐related nausea and vomiting: the state of the art
7. Behavioral treatment for the anticipatory nausea and vomiting induced by cancer chemotherapy
8. Anticipatory nausea and vomiting in pediatric cancer patients
9. Anticipatory nausea and emotional distress in patients receiving cisplatin‐based chemotherapy
10. Chemotherapy‐related nausea and vomiting: etiology and management
11. The management of chemotherapy‐induced nausea and vomiting
12. Definitional issues in the study of anticipatory nausea in cancer chemotherapy
13. The pharmacology and clinical effectiveness of phenothiazines and related drugs for managing chemotherapy‐induced emesis
14. Specific antiemetics for specific cancer chemotherapeutic agents: haloperidol versus benzquinamide
15. Cardiovascular dopamine receptor stimulation antagonized by metoclopramide
16. Substituted benzamides as anti‐emetics
17. Metoclopramide, an updated review of its pharmacological properties and clinical use
18. Anti‐emetic efficacy of high dose metoclopramide: Randomised trials with placebo and prochlorperazine in patients with chemotherapy‐induced nausea and vomiting
19. Inhibition of cisplatin‐induced vomiting by selective 5‐hydroxytryptamine M‐receptor antagonism
20. The 5‐hydroxytryptamine receptor antagonists as antiemetics: preclinical evaluation and mechanism of action
21. 3 receptor in the anaesthetized ferret
22. 3 receptor antagonists injected into the area postrema inhibit cisplatin‐induced emesis in the ferret
23. Advances in anti‐emetic therapy
24. On the receiving end ‐ patient perception of the side effects of cancer chemotherapy
25. How should nausea be assessed in patients receiving chemotherapy?
26. Cancer therapy, vomiting, and antiemetics
27. Anticipatory vomiting in women receiving cyclophosphamide, methotrexate, and 5‐FU (CMF) adjuvant chemotherapy for breast carcinoma
28. The control of cancer chemotherapy‐induced nausea and vomiting
29. Etiology and treatment of the psychological side effects associated with cancer chemotherapy
30. Prevalence, predictors, and course of anticipatory nausea in women receiving adjuvant chemotherapy for breast cancer
31. Nonpharmacologic factors in the development of posttreatment nausea with adjuvant chemotherapy for breast cancer
32. Making chemotherapy easier
33. Optimum management of nausea and vomiting in cancer chemotherapy
34. The influence of administration time on chemotherapy‐induced nausea and vomiting
35. Recent advances in the pharmacologic and behavioral management of chemotherapy‐induced emesis
36. Relaxation training for control of nausea and vomiting in patients receiving chemotherapy
37. Effectiveness of biofeedback and relaxation training in reducing the side effects of cancer chemotherapy
38. Behavioral interventions in cancer treatment: controlling aversion reactions to chemotherapy
39. A preliminary report on the efficacy of hypnosis to control anticipatory nausea and vomiting caused by cancer chemotherapy
40. Anticipatory nausea and emesis: behavioral interventions
41. Recent advances in the management of nausea and vomiting caused by antineoplastic agents
42. 3 antagonists
43. Neuronal 5‐HT receptors in the periphery
44. Methylprednisolone as an antiemetic
45. Antiemetic efficacy of dexamethasone therapy in patients receiving cancer chemotherapy
46. High‐dose dexamethasone for prevention of cisplatin‐induced vomiting
47. Antiemetics in patients receiving chemotherapy for cancer: a randomized comparison of delta‐9‐tetrahydrocannabinol and prochlorperazine
48. Delta‐9‐tetrahydrocannabinal in cancer chemotherapy: research problems and issues
49. A prospective evaluation of delta‐9‐tetrahydrocannabinol as an antiemetic in patients receiving Adriamycin and Cytoxan chemotherapy
50. Lorazepam in cancer patients treated with cisplatin: a drug having antiemetic amnesic, and anxiolytic effects
51. Identification of serotonin M‐receptor subtypes and their specific blockage by a new class of drugs
52. Pharmacological properties of GR38032F, a novel antagonist at 5‐HT3 receptors
53. 3 receptor antagonist
54. The efficacy of granisetron as a prophylactic anti‐emetic and intervention agent in high‐dose cisplatin‐induced emesis
55. On behalf of the Granisetron Study Group. A comparison of two dose levels of granisetron in patients receiving high‐dose cisplatin
56. On behalf of the Granisetron Study Group. A comparison of two dose levels of granisetron in patients receiving moderately emetogenic cytostatic chemotherapy
57. on behalf of the Granisetron Study Group. Intravenous granisetron—establishing the optimal dose
58. Protection from nausea and vomiting in cisplatin‐treated patients: high‐dose metoclopramide combined with dexamethasone and diphenhydramine: a study of the Italian Oncology Group for Clinical Research
59. Progressive loss of antiemetic efficacy during subsequent courses of chemotherapy
60. On behalf of the Granisetron Study Group. Does granisetron remain effective over multiple cycles?
61. On behalf of the Granisetron Study Group. Fractionated chemotherapy—granisetron or conventional antiemetics?
62. Predictive factors of delayed emesis in cisplatintreated patients and antiemetic activity and tolerability of metoclopramide or dexamethasone
63. Controlling delayed vomiting: Double‐blind randomised trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin
64. 3 receptor antagonist: an overview of their present status and future potential in cancer therapy‐induced emesis
65. 3 antagonist
66. An overview on the use of granisetron in the treatment of emesis associated with cytostatic chemotherapy
67. Prevention of emesis in patients receiving cytotoxic drugs by GR38032F, a selective 5‐HT3 receptor antagonist
68. 3 (serotonin) antagonist ondansetron (GR 38032F) with high‐dose metoclopramide in the control of cisplatin‐induced emesis
69. Ondansetron compared with high‐dose metoclopramide in prophylaxis of acute and delayed cisplatin‐induced nausea and vomiting
70. Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin induced nausea and vomiting
71. A randomized, double‐blind comparison of oral ondansetron and placebo in the prophylaxis of CMF‐induced nausea and vomiting [abstract]
72. The role of ondansetron in the treatment of emesis induced by non‐cisplatin‐containing chemotherapy regimes
73. A comparison of ondansetron with metoclopramide in the prophylaxis of chemotherapy‐induced nausea and vomiting: a randomized, double‐blind study
74. On behalf of the Granisetron Study Group. A comparison of granisetron as a single agent with conventional combination antiemetic therapies in the treatment of cytostatic‐induced emesis
75. Maintenance of antiemetic effectiveness with multiple courses of GR38032F and cisplatin [abstract]
76. Ondansetron: A new antiemetic for patients receiving cisplatin chemotherapy
77. A double‐blind randomised comparison of three doses of i.v. ondansetron for the prevention of emesis induced by multiday cisplatin therapy (abstract)
78. GR38032F: A new antiemetic effective in a multiple day regimen of cisplatin (DDP) chemotherapy (abstract)
79. Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy
80. Does dexamethasone enhance control of acute cisplatin induced emesis by ondansetron?
81. Comparison of ondansetron and ondansetron plus dexamethasone as antiemetic prophylaxis during cisplatin‐containing chemotherapy
82. GR 38032F (GR‐C507/75): A novel compound effective in the prevention of acute cisplatin‐induced emesis
83. Controlling emesis related to cancer therapy
84. Extrapyramidal reaction to ondansetron
85. First results with ICS 205‐930 (5‐HT receptor antagonist) in prevention of chemotherapy‐induced emesis
86. 3 antagonist) on cisplatin‐induced nausea and vomiting
87. Phase I antiemetic study of the serotonin antagonist ICS 295‐930 (abstract)
88. Tropisetron: A review of the clinical experience
89. Three years experience with tropisetron in the control of nausea and vomiting in cisplatin‐treated patients
90. Tropisetron in the prevention of chemotherapy‐induced nausea and vomiting: The Nordic experience
91. Prevention of chemotherapy‐induced nausea and emesis in patients responding poorly to previous antiemetic therapy: comparing tropisetron with optimised standard anti‐emetic therapy
92. Tropisetron plus haloperidol to ameliorate nausea and vomiting associated with high‐dose alkylating agent cancer chemotherapy
93. 3 receptor antagonists, tropisetron, in patients refractory to standard antiemetic treatment
94. Tropisetron in the control of nausea and vomiting induced by combined cancer chemotherapy in children
95. Efficacy and tolerability of tropisetron and dexamethasone in the control of nausea and vomiting
96. 3 receptor antagonists the same?
97. Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: A phase III trial by the National Cancer Institute of Canada Clinical Trials Group
98. On behalf of The Granisetron Study Group. A double blind, randomised, crossover comparison of granisetron and ondansetron in 5 day fractionated chemotherapy: assessment of efficacy, safety and patient preference
99. Granisetron (GRA) vs. ondansetron (OND) in the prevention of cisplatinum‐induced emesis: an open randomized cross‐over study [abstract]
100. Ondansetron compared with granisetron in the prophylaxis of cisplatin‐induced Acute emesis: a multicentre double‐blind, randomised, parallel‐group study
101. Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin‐induced emesis
102. Ondansetron compared with granisetron in the prophylaxis of cyclophosphamide‐induced emesis in out‐patients: a multicentre, double‐blind, double‐dummy, randomised, parallel‐group study
103. Ondansetron and tropisetron with dexamethasone in the prophylaxis of acute vomiting induced by non‐cisplatin‐containing chemotherapy
104. 3 receptor antagonists in the prophylaxis of acute vomiting induced by highly emetogenic chemotherapy (high dose cisplatin) for the treatment of primary head and neck cancer [abstract]
105. 3 receptors [abstract]
106. 3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy ‐ a randomized study
107. Review of experience with ondansetron and granisetron
108. 3 receptor antagonists in the management of chemotherapy‐induced emesis
109. Ondansetron: costs and resources utilisation in a US teaching hospital setting
110. Control of chemotherapy‐induced emesis
111. Ondansetron: a specific seratonin antagonist for the prevention of chemotherapy‐induced vomiting
112. Odansetron: “a new concept in the management of emesis
113. Serotonin‐Mediated emesis: the role of ondansetron
114. Behavioral treatment of chemotherapy‐induced nausea and emesis: effectiveness and clinical implications
115. How do patients and physicians decide which antiemetic is the best in a cross‐over study [abstract]?
116. Are granisetron and ondansetron equivalent in the clinic?